• Du J, Zhou L, Chen X, Yan S, Ke M, Lu X, Wang Z, Yu W, Xiang AP. 2012. IFN-γ-primed human bone marrow mesenchymal stem cells induce tumor cell apoptosis in vitro via tumor necrosis factor-related apoptosis-inducing ligand. Int J Biochem Cell Biol 44:13051314.
  • Ehrlich S, Infante-Duarte C, Seeger B, Zipp F. 2003. Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes. Cytokine 24:244253.
  • Fanger NA, Maliszewski CR, Schooley K, Griffith TS. 1999. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 190:11551164.
  • Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA. 1999. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 189:134354.
  • Hayakawa Y, Sato-Matsushita M, Takeda K, Iwakura Y, Tahara H, Irimura T. 2011. Early activation and interferon-γ production of tumor-infiltrating mature CD27 high natural killer cells. Cancer Sci 102:19671971.
  • Humphreys RC, Halpern W. 2008. Trail receptors: targets for cancer therapy. Adv Exp Med Biol 615:127158.
  • Jarahian M, Watzl C, Fournier P, Arnold A, Djandji D, Zahedi S, Cerwenka A, Paschen A, Schirrmacher V, Momburg F. 2009. Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J Virol 83:81088121.
  • Krammer PH. 1999. CD95 (APO-1/Fas)-mediated apoptosis: live and let die. Adv Immunol 71:163210.
  • LeBlanc HN, Ashkenazi A. 2003. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10:6675.
  • Liabakk NB, Sundan A, Torp S, Aukrust P, Frøland SS, Espevik T. 2002. Development, characterization and use of monoclonal antibodies against sTRAIL: measurement of sTRAIL by ELISA. J Immunol Methods 259:119128.
  • Lorence RM, Rood PA, Kelley KW. 1988. Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-α and augmentation of its cytotoxicity. J Natl Cancer Inst 80:13051312.
  • Lub-de Hooge MN, de Vries EG, de Jong S, Bijl M. 2005. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis 64:854858.
  • Mérino D, Lalaoui N, Morizot A, Solary E, Micheau O. 2007. TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets 11:12991314.
  • Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, Yagita H, Okumura K. 2001. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon γ-dependent natural killer cell protection from tumor metastasis. J Exp Med 193:661670.
  • Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K. 2001. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7:94100.
  • Tu Z, Hamalainen-Laanaya HK, Crispe IN, Orloff MS. 2011. Synergy between TLR3 and IL-18 promotes IFN-γ dependent TRAIL expression in human liver NK cells. Cell Immunol 271:286291.
  • Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. 1999. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17:331367.
  • Wertz K, Büttner M, Mayr A, Kaaden OR. 1994. More than one component of the Newcastle disease virus particle is capable of interferon induction. Vet Microbiol 39:299311.
  • Zahn S, Rehkämper C, Ferring-Schmitt S, Bieber T, Tüting T, Wenzel J. 2011. Interferon-α stimulates TRAIL expression in human keratinocytes and peripheral blood mononuclear cells: implications for the pathogenesis of cutaneous lupus erythematosus. Br J Dermatol 165:11181123.
  • Zorn U, Dallmann I, Grosse J, Kirchner H, Poliwoda H, Atzpodien J. 1994. Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother 9:225235.